Iron is essential for normal cellular functioning of the central nervous system. Abnormalities in iron metabolism may lead to neuronal death and abnormal iron deposition in the brain. Several studies have suggested a link between brain iron deposition in normal aging and chronic neurologic diseases, including multiple sclerosis (MS). In MS, it is still not clear whether iron deposition is an epiphenomenon or a mediator of disease processes. In this review, the role of iron in the pathophysiology of MS will be summarized. In addition, the importance of conventional and advanced magnetic resonance imaging techniques in the characterization of brain iron deposition in MS will be reviewed. Although there is currently not enough evidence to support clinical use of iron chelation in MS, an overview of studies of iron chelation or antioxidant therapies will be also provided.
Introduction
Iron is critical for normal brain functioning. However, aberrant iron metabolism and abnormal iron deposition in the brain are associated with many neurologic disorders including multiple sclerosis (MS) (Stankiewicz and Brass, 2009) . Several possible causes of abnormal iron deposition in MS have been postulated including blood-brain barrier dysfunction, decreased iron clearance because of axonal dysfunction and inflammation, or dysregulation of iron transport proteins because of inflammation . Abnormal iron homeostasis may contribute to the neurodegeneration seen in MS.
Magnetic resonance imaging (MRI) studies have shown that excessive iron accumulates in the gray matter (GM) of MS patients, mainly in the basal ganglia. Recently, the use of advanced MRI techniques and ultraehigh-field MRI has aided characterization of iron deposits in both the GM and white matter (WM) of patients with MS. However, further MRI optimization will enhance our understanding of iron's role in MS pathophysiology. Combined histopathologic MRI studies have begun to elucidate the role of iron deposition in MS pathology. More investigation in MS is required to clarify whether either chelation or antioxidant treatments represent a viable therapeutic alternative.
In this article, we will provide an overview of research related to the normal iron homeostasis and role of iron in the pathophysiology of MS. Recent data from key original reports regarding the role of conventional and advanced MRI techniques in the assessment of iron deposition in MS will be explored. We will also focus on the most relevant therapeutic intervention studies with respect to both animal and human models that have added to the current understanding of iron toxicity in MS.
Iron metabolism
The maintenance of proper iron concentrations in the body is vital to optimal functioning. Iron is involved in many crucial processes including myelin production, oxygen transport, glucose metabolism, synthesis of neurotransmitters, and DNA replication (Pinero and Connor, 2000) . It is, therefore, unsurprising that iron deficiency at birth can impair normal cognitive development. Iron deficiency later in life may lead to cognitive impairment, attentional problems, or restless leg syndrome (Beard, 2003) . Conversely, too much iron can also cause neurologic disease. Neuroferritinopathy, a disorder of movement characterized by extrapyramidal symptoms, is thought to be because of a mutation in ferritin light chain gene 1 resulting in ferritin and iron accumulation in the brain (Mancuso et al., 2005) .
Normally, elimination of iron from the body is fairly consistent and occurs from either bleeding or shedding of cells from the skin or gut. Consequently, iron concentration in the body is regulated by control of iron intake from food ( Fig. 1) .
Iron trafficking in the body

Entry through the gut
Iron is absorbed via the gut, most often in the duodenum through the crypts of Lieberkühn. For iron to enter the bloodstream, it must pass through the gut cells. On the intestinal luminal side, mechanisms involving ferrireductase duodenal cytochrome b activity and divalent metal transporter 1 (DMT1) are involved in entry into the enterocyte (De Domenico et al., 2008) . Export from the basolateral side of the enterocyte involves ferroportin and hephaestin. Hepcidin and hemochromatosis protein 2 are thought to interact to determine how much iron is admitted to the bloodstream via a feedback loop (Pantopoulos et al., 2012) . In the bloodstream, iron circulates in the blood bound to transferrin (Tf) (Fig. 2) .
Cellular iron transport and homeostasis
Transferrin receptor (TfR) and Tf mediate cellular uptake. Tf and TfR have a high binding affinity for one another. These binding complexes are taken up by cells via clathrin-coated pits. After acidification in the endosome, iron is released from Tf and is exported into the cytoplasm by DMT1 (De Domenico et al., 2008) . Dissociated Tf and TfR are exported back to the cell surface, and Tf reenters the bloodstream (Dautry-Varsat et al., 1983) . Regulation of cellular iron levels are achieved through feedback loops involving iron-response proteins and iron-response elements that are involved in translation of ferritin, TfR, and other regularly proteins. Further details can be found in an excellent review by Rouault (2006a) .
Iron trafficking and distribution in the brain
Brain iron transit
Iron intake in the brain is also rigorously regulated and interacts with other metals such as copper (Skjørringe et al., 2012) . It can enter the brain through the blood-brain barrier and blood-cerebrospinal fluid barrier, which exists between the blood and the choroid plexus (Skjørringe et al., 2012) . Most commonly, iron-bound Tf in the blood is captured by TfR found on brain endothelial cells, and this complex is then endocytosed. Once iron has crossed into the central nervous system, it is released from Tf into the interstitium (Benarroch, 2009) . Brain iron homeostasis is tightly regulated, and this balance is achieved in a similar way to peripheral control of intracellular iron (Rouault and Cooperman, 2006b ). Currently, the mechanisms for iron egress from the brain are poorly understood. Brain iron is likely reabsorbed back into the bloodstream via the cerebrospinal fluid through the subarachnoid space (Benarroch, 2009) (Fig. 3) .
Normal cellular and structural distribution of iron in the brain
Starting at low levels at birth, brain iron concentration increases rapidly over the first 2 decades of life and then rises more slowly thereafter (Hallgren and Sourander, 1958) . Oligodendrocytes and astrocytes acquire solely noneTf-bound iron, whereas neurons have both TfRs and DMT1 (Moos et al., 2007) . Although monocytes and macrophages contain iron to promote free radicals as part of respiratory burst activity, brain microglia rarely contain iron. Iron can also be stored in the central nervous system bound not only to stable ferritin but also to more reactive substances like neuromelanin and hemosiderin. In the normal brain, the highest concentrations of iron are found in the globus pallidus, caudate nucleus, putamen, dentate nucleus, red nucleus, and substantia nigra (Aoki et al., 1989) .
Imaging brain iron deposition in multiple sclerosis
MRI is a powerful tool to detect and quantify brain iron deposition in vivo. Among all the brain's essential metals, brain iron concentrations are normally high enough to affect the MRI signal . Iron can be found as heme iron, such as in hemoglobin, or non-heme iron. Unlike heme iron, failure to achieve homeostasis of non-heme iron metabolism has been associated with neurodegeneration (Madsen and Gitlin, 2007) . Although MRI is not able to accurately differentiate between heme iron and non-heme iron in vivo, it is suggested that ferritin and hemosiderin are the only types of non-heme iron responsible for MRI signal changes (Haacke et al., 2005; Schenck and Zimmermann, 2004) . Other non-heme iron forms, such as the free liable iron pool or Tf-bound iron, do not seem to influence the MRI signal because of their low concentration (Haacke et al., 2005; Schenck and Zimmermann, 2004) . Brain iron accumulation shortens the longitudinal (T1) and transverse (T2) relaxation times of the mobile protons in the brain resulting in signal loss or hypointensity on T2-weighted images (T2 hypointensity) and hyperintensity on T1-weighted images (T1 hyperintensity). Building on these principles, several pulse sequences and quantitative MRI techniques have been developed and employed in detection and quantification of iron in the brain. The use of highfield (3 T) and ultraehigh-field (>3 T) MRI has further facilitated the detection of brain iron in both GM and WM. In the following sections, the role of iron in the pathophysiology of MS and its link to neuroinflammation, neurodegeneration, and clinical status is described.
GM iron deposition
A common finding in patients with MS on spin-echo T2-weighted clinical MRI scans is diffuse hypointensity of the cortical and deep GM areas (e.g., the red nucleus, thalamus, dentate nucleus, lentiform nucleus, caudate, and rolandic cortex) versus age-matched normal controls (Fig. 4) .
T2 hypointensity in GM has been shown to be associated with brain atrophy, disability progression, and cognitive impairment in patients with MS (Bakshi et al., 2000 (Bakshi et al., , 2001 (Bakshi et al., , 2002 Bermel et al., 2005; Brass et al., 2006a Brass et al., , 2006b Ceccarelli et al., 2009 Ceccarelli et al., , 2010 Ceccarelli et al., , 2011 Drayer et al., 1987a Drayer et al., , 1987b Neema et al., 2007 Neema et al., , 2009 Neema et al., , 2012 Tjoa et al., 2005; Zhang et al., 2007 Zhang et al., , 2010 . T2 hypointensity, as a sign of excessive GM iron deposition, has been shown to be present in all MS subtypes (Bakshi et al., 2000 (Bakshi et al., , 2001 (Bakshi et al., , 2002 Bermel et al., 2005; Brass et al., 2006a Brass et al., , 2006b Ceccarelli et al., 2009 Ceccarelli et al., , 2010 Ceccarelli et al., , 2011 Drayer et al., 1987a Drayer et al., , 1987b Neema et al., 2007 Neema et al., , 2009 Tjoa et al., 2005; Zhang et al., 2007 Zhang et al., , 2010 . Although iron has emerged as a surrogate marker for neurodegeneration in MS, it still remains unclear whether iron deposition is simply an epiphenomenon resulting from brain tissue degeneration or if it directly contributes to brain damage in MS.
Recent T2 intensity studies involving early and milder forms of MS (Ceccarelli et al., 2009 (Ceccarelli et al., , 2010 (Ceccarelli et al., , 2011 have begun to bridge gaps in knowledge regarding the role of iron deposition in the pathophysiology of the disease. In patients with clinically isolated syndrome (CIS), lower T2 intensity in the caudate nucleus was found compared with healthy controls (Ceccarelli et al., 2010) . In patients with established MS, T2 hypointensity best predicted disability progression over time and was a better marker of disability than other measures such as whole brain atrophy and T2-lesion volume ). In contrast, in CIS patients, T2 hypointensity of deep GM was not associated with subsequent evolution to clinically definite MS (Ceccarelli et al., 2010) . Further evidence that iron could accumulate early in the disease course has been provided by studies in pediatric MS patients (Ceccarelli et al., 2011) . Like CIS, selective T2 hypointensity was found in the caudate nucleus of pediatric MS patients with a sparing of other deep GM structures (Ceccarelli et al., 2011) . Furthermore, despite their favorable clinical course and the lower overall brain tissue damage, similar T2 intensity was found in benign MS patients compared with secondary progressive MS patients (Ceccarelli et al., 2009 ). Taken together, these findings suggest that brain iron accumulation occurs early in the disease course and increases with disease duration. Few studies have looked at the effect of treatment on brain T2 signal change (Bermel et al., 2005; Pawate et al., 2012) . A recent longitudinal year long pilot study of natalizumab treatment of MS patients (Pawate et al., 2012) showed a treatment effect on limiting progression of T2 hypointensity in GM, suggesting that impeding the inflammatory cascade could lead to decreased iron deposition in the brain. Although T2 intensity studies have provided important clues regarding iron accumulation in the brain of MS patients, the effects of various other confounding factors, such as water content, make the T2 intensity method a nonspecific indicator for estimating iron levels . Because of their increased sensitivity to iron-related susceptibility changes, new advanced quantitative MRI techniques, and related postprocessing analysis, combined with the use of high-field and ultraehigh-field strength MRI, are currently being employed to further define the role of iron in MS (Bagnato et al., 2013; Ge et al., 2007; Habib et al., 2012; Hagemeier et al., 2012a Hagemeier et al., , 2013a Hagemeier et al., , 2013b Hammond et al., 2008; Khalil et al., 2009 Khalil et al., , 2011a Khalil et al., , 2011b Lebel et al., 2012; Pitt et al., 2010; Ropele et al., 2011; Rumzan et al., 2013; Walsh et al., 2014; Zivadinov et al., 2012) . To date, most of these MRI studies have significantly improved the detection of abnormal iron deposition in cortical and deep GM and confirmed its clinical relevance in MS (Bagnato et al., 2013; Ge et al., 2007; Habib et al., 2012; Hagemeier et al., 2012a Hagemeier et al., , 2013a Hagemeier et al., , 2013b Hammond et al., 2008; Khalil et al., 2009 Khalil et al., , 2011a Khalil et al., , 2011b Lebel et al., 2012; Pitt et al., 2010; Ropele et al., 2011; Rumzan et al., 2013; Walsh et al., 2014; Zivadinov et al., 2012) . Interestingly, using 7-T MRI and quantitative magnetic susceptibility mapping (Al-Radaideh et al., 2013), iron deposition in several deep GM areas, including the caudate, putamen, pallidus, and pulvinar nucleus, has been shown in CIS patients, further supporting and extending previous findings (Ceccarelli et al., 2010) . Recently, a study using susceptibility-weighted filtered phase imaging found that GM iron-related changes may precede GM atrophy in CIS patients suggesting that abnormal iron deposition may be an early surrogate of the disease (Hagemeier et al., 2012a) .
Although the measures of GM iron deposition hold promise as clinically relevant biomarkers, more work is necessary before these techniques find use in clinical practice to inform care for individual patients.
WM iron deposition
Pathologic studies have shown that iron accumulation in the WM is mainly present at the level of MS lesions (Craelius et al., 1982; Hametner et al., 2013) and near the veins (Adams, 1988) . However, MRI detection of iron deposition in the WM is still challenging because of the confounding effect on the MRI signals of edema, inflammation, gliosis, and myelin content (Langkammer et al., 2010; Neema et al., 2007; Walsh et al., 2013; Yao et al., 2012) . The application of multimodal approach of advanced iron-sensitive MRI techniques, such as phase imaging, R2*, and ultraehigh-field scanners, has enhanced the current understanding of WM iron deposition in MS. In particular, with the use of phase imaging, it is possible to visualize phase hypointense WM lesions that are likely high in iron content and often missed by conventional MRI sequences (Eissa et al., 2009; Haacke et al., 2009; Hagemeier et al., 2012b; Hammond et al., 2008) . Various phase hypointense WM MS lesion patterns have also been identified such as nodular, ring, and scattered shapes, suggesting that iron deposition could be inside or at the edge of phase WM lesions in MS (Eissa et al., 2009; Haacke et al., 2009; Hagemeier et al., 2012b) . Such phase WM lesions have also been observed even at the earliest clinical stages of MS (Hagemeier et al., 2012b) . Although the interplay between various cellular structures is thought to be responsible for the diverse hypointense patterns in the WM lesions (Bagnato et al., 2011; Bian et al., 2013; Mehta et al., 2013) , the mechanisms behind these have yet to be elucidated. In addition, a reliable MRI method to characterize the presence of iron in WM is currently unavailable (Walsh et al., 2013; Yao et al., 2012) . Future combined histopathologicmultimodal MRI studies will shed light on the mechanisms underlying iron-related MRI changes seen in WM, which in turn may provide insights into understanding the link between WM damage and clinical status. . T2 hypointensity in multiple sclerosis (MS): T2-weighted fast spin-echo axial magnetic resonance imaging scans obtained at 1.5 T of a healthy control (A) in the fifth decade and an age-matched patient with relapsing-remitting MS (B). In the patient with MS, note bilateral hypointensity of various deep gray matter areas, including the thalamus, lentiform nucleus, and caudate compared with the healthy control. This T2 hypointensity most likely represents pathologic iron deposition. The patient also has brain atrophy. Reprinted from Neema et al. (2012) with permission from the publisher.
Iron toxicity
Bound iron is considered "safe," but free iron is more likely to exchange electrons with nearby molecules and produce free radicals. Normal metabolic processes in the mitochondria form hydrogen peroxide as the result of molecular reduction of oxygen. Hydrogen peroxide alone is not particularly toxic, but in the presence of free iron (Fe2þ), a free radical (•OH) is formed when free iron donates an electron to hydrogen peroxide via the Fenton reaction. This free radical can interact with oxygen and other molecules in the brain to form more free radicals propagating a deleterious positive feedback loop. Hydroxyl radicals can attack proteins, deoxynucleic acids, and lipid membranes. This process can disrupt cellular integrity and function eventually leading to cell apoptosis (Halliwell, 2006) . Oxidative stress has been implicated in the pathogenesis of MS, potentially contributing to both demyelination and axonal damage (Gilgun-Sherki et al., 2004) .
Protection from iron-mediated damage
Endogenous protection
Experimental work suggests that the body has natural processes in place to stem potentially damaging free-radical formation. Both glutathione and vitamin E have been implicated as protective. Glutathione in a reduced state interacts with hydrogen peroxide and other organic peroxides to yield an oxidized form of glutathione, water, and alcohol. Removal of hydrogen peroxide leaves less potential for interaction with free iron and less subsequent production of hydroxyl radicals. Cells able to survive potentially to toxic iron show increased glutathione production (Aguirre et al., 2006) . A form of vitamin E (alpha-tocopherol) can act as an antioxidant by donating a proton to reactive oxygen species, thus making them more stable and less reactive (Crichton et al., 2002) . Experimental work finds that cerebellar granule cell cultures and hippocampal neurons treated with iron in the presence of either alpha-tocopherol or an analogue were better preserved (de Jesus Ferreira et al., 2005; Van der Worp et al., 1999) .
Exogenous protection
Because iron may contribute to the pathogenesis of MS, human and animal investigations have been performed to ascertain whether binding iron (chelation) or reducing iron associated freeradical damage (antioxidants) might represent viable treatment strategies.
Chelation
Iron chelators may attenuate free-radical toxicity by binding circulating free iron and preventing this iron from participating in redox reactions. Iron chelation therapy has been tried in the experimental autoimmune model of MS with some success. A study conducted in experimental autoimmune encephalomyelitis (EAE) induced by spinal cord homogenates showed a response to desferrioxamine (Bowern et al., 1984) . Two other studies investigated desferrioxamine in a myelin basic protein-induced EAE model. Willenborg et al. (1988) found no response if the desferrioxamine was administered in a preclinical phase, whereas Pedchenko and LeVine (1999) found that if the desferrioxamine was administered later, during a time of clinical symptoms, it effectively attenuates the disease. The short half-life of desferrioxamine, potential critical window for effect, or other free-radical scavenging effects outside iron binding might account for the discrepant studies. Pedchenko and Levine (1999) also reported that dexrazoxane, another iron chelator similar to desferrioxamine but with a longer half-life also attenuated the course of EAE, but its effect was less robust than that seen with desferrioxamine. Also, rats given dexrazoxane in conjunction with mitoxantrone experienced more improvement on clinical indices than rats treated solely with mitoxantrone (Weilbach et al., 2004) .
Only 1 human trial using desferrioxamine has been conducted in a small group of secondary progressive MS patients (Lynch et al., 2000) . Nine patients received up to 8 courses of desferrioxamine, and although the drug was well tolerated, little effect was seen on disability. Specifically, a single patient improved, 3 patients were unchanged, and 5 patients worsened. These disappointing results call into question whether treatment with desferrioxamine (or iron chelation more generally) could be an effective treatment strategy for MS. It is worth noting, however, that this trial was small and that the enrolled patients had more advanced disease. Patients with higher disability typically have been refractory to treatment in MS drug trials.
It is clear that iron deposition occurs in MS and that iron chelation can work in the EAE model. It remains to be seen, however, whether chelation therapy can be a successful treatment strategy in MS.
Antioxidants
Antioxidants might help counteract iron's role in disease by protecting the body from oxidative stresses. A study of MS plaques revealed decreased levels of antioxidants and increased free-radical activity (Langemann et al., 1992) . MS patients also exhibit increased levels of oxidative stress markers compared with normal controls, with correlation seen between disability and higher levels of oxidative stress markers (Oliveira et al., 2012) .
Many antioxidants have been suggested to be neuroprotective through reduction of free-radical formation including vitamin A, vitamin C, vitamin E, coenzyme Q10, green tea extract, nitric oxide, selegiline (monoamine oxidase inhibitor with antioxidant properties), and Ginkgo biloba.
A full accounting of antioxidants that have been successful in attenuating the EAE model of MS is outside the scope of this review, but many have succeeded. Commonly recognized antioxidants that work on an EAE model include vitamin A (Massacesi et al., 1987) , vitamin C (Spitsin et al., 2002) , lipoic acid (Marracci et al., 2002) , resveratrol (Shindler et al., 2010) , blueberries (Xin et al., 2012) , green tea (Aktas et al., 2004) , and curcumin (Xie et al., 2009) . Although these antioxidants can show an effect in animals, it is not always clear that this effect is because of reduction of free radicals. For example, experimental work with green tea extract demonstrates that this compound affects T cells . It is also worth noting that some antioxidants such as idebenone have failed to provide a beneficial effect in the EAE model (Fiebiger et al., 2013) .
Few human trials of antioxidants have been performed. Perhaps, the most visible drug with potential antioxidant effect in the MS space is the recently Food and Drug Administrationeapproved dimethyl fumarate. Although argument remains about how the drug is having its treatment effect on MS, experiments suggest that the drug works on a free-radical scavenging pathway (Nrf2) and has antioxidant effects (Linker et al., 2011) . Another drug, inosine, has been trialed in 2 separate MS cohorts. This precursor drug is metabolized to the antioxidant uric acid. Although successful in an EAE model, inosine has shown mixed results in relapsing-remitting MS patients. Gonsette et al. (2010) did not show a benefit from the drug. Markowitz et al. (2009) found that MS patients with higher serum urate levels did benefit from inosine compared with their pretreatment state. Renal calculi were seen in both the Gonsette (3.8%) and Markowitz (25%) trials. Double-blind placebo-controlled studies with increased enrollment and longer observation periods are needed before conclusions about long-term efficacy and safety of antioxidants can be made.
Conclusions
We have reviewed the physiology of iron metabolism and the role of abnormal brain iron deposition in MS. We have seen that although iron is vital for normal neuronal processes, abnormal iron accumulation may cause neurodegeneration through lipid peroxidation and cell death in the brain. Human MRI studies reported an association between abnormal brain iron deposition and clinical dysfunction in MS patients. It remains to be elucidated whether iron deposition is a marker or mediator of the destructive cascade in MS. Future studies incorporating newer pulse sequences, multimodal MRI in conjunction with histopathologic assessments, and novel postprocessing techniques should shed light on mechanisms responsible for abnormal iron deposition and on its role in the pathogenesis of MS. Animal models of MS have shown a neuroprotective effect by either iron chelation or antioxidants; however, in MS patients, the effectiveness of these pharmacologic modification is still debatable and requires further investigation.
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